Affiliate sales disclosed for Adaptive Biotechnologies (NASDAQ: ADPT) in Form 144
A Form 144 filing reveals proposed sales of common stock by an affiliate, Chad M. Robins, for Adaptive Biotechnologies (NASDAQ: ADPT). The filing details multiple transactions ranging from 4,452 to 99,225 shares, with corresponding gross proceeds indicated for each. These are routine notices, and the filing does not confirm whether the sales were executed.
ADPT Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Adaptive Biotechnologies Corp (ADPT). It details the overall technical consensus, moving averages, momentum indicators like RSI and MACD, and key support and resistance levels. The analysis concludes with a "Buy" technical sentiment, based on various indicators and moving average performance, including trading above its 200-day moving average.
Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 24,233 shares of ADPT stock for approximately $392,329 in early March 2026. These sales were conducted under a Rule 10b5-1 trading plan adopted in August 2025. Despite the insider sale, ADPT shares have shown significant returns over the past year, and the company recently surpassed analyst expectations for its Q4 2025 earnings, leading to increased price targets from TD Cowen and BTIG.
Adaptive Biotechnologies (ADPT) COO exercises options and sells 38K shares
Adaptive Biotechnologies (ADPT) President and COO Julie Rubinstein exercised stock options and simultaneously sold 38,120 shares of common stock. These transactions were pre-planned under a Rule 10b5-1 trading plan adopted on November 18, 2025. Following these trades, Rubinstein directly holds 447,202 shares of Adaptive Biotechnologies common stock.
Adaptive Biotechnologies president sells $553,693 in ADPT stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 38,120 shares of company stock for approximately $553,693 and exercised options to acquire 29,444 shares. The stock has seen an 86.5% gain over the past year but is considered overvalued by InvestingPro analysis. This news follows the company's strong Q4 2025 earnings, which surpassed analyst expectations and led to increased price targets from BTIG, TD Cowen, and Piper Sandler.
Adaptive Biotechnologies (ADPT) president sells $751k in stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 57,180 shares of company stock for approximately $751,302 between March 27 and March 31, 2026, while also exercising options for 44,166 shares. These transactions, executed under a Rule 10b5-1 trading plan, occurred as the stock showed significant volatility despite an 86.81% return over the past year. Analysts do not anticipate profitability this year, and the company appears overvalued, although recent Q4 2025 earnings surpassed expectations, leading to raised price targets from several analyst firms.
ADPT Stock News Today | Earnings, Events & Price Alerts
This page provides recent news and event updates for Adaptive Biotechnologies (ADPT), including details on executive stock sales and significant Q4 2025 earnings. The company reported strong revenue growth, especially in its MRD business, and anticipates continued growth and profitability in 2026. Recent insider stock transactions and an analysis of competitive concerns are also highlighted.
ADPT PE Ratio & Valuation, Is ADPT Overvalued
Adaptive Biotechnologies Corp (ADPT) is currently considered undervalued, with its forward PS ratio of 6.41 being lower than its five-year average. The fair price for ADPT is estimated to be between $28.75 and $61.70, significantly higher than its current price of $14.81, indicating a potential undervaluation of 48.49%. Despite this, its current P/B ratio and revenue growth suggest a sustainable premium compared to the industry average.
Adaptive Biotechnologies (ADPT) president sells $751k in stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), sold 57,180 shares of common stock for approximately $751,302 between March 27 and March 31, 2026. These transactions, executed under a Rule 10b5-1 trading plan, followed Rubinstein's exercise of stock options. Despite the sale, the company recently reported strong Q4 2025 earnings, surpassing analyst expectations, and received raised price targets and reiterated positive ratings from several analyst firms.
Adaptive Biotech (NASDAQ: ADPT) COO sells 57,180 shares in 10b5-1 plan
Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), sold 57,180 shares of common stock in open-market transactions in late March. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, followed the exercise of stock options for 44,166 shares. After these transactions, Rubinstein directly holds 455,878 shares of the company's common stock.
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake
Adaptive Biotechnologies (ADPT) stock experienced a significant 24.5% decline. This sharp drop occurred as company executives disposed of millions of dollars worth of their stakes, likely contributing to investor concern and the downward pressure on the stock price.
Adaptive Biotechnologies’ president Rubinstein sells $802k in ADPT stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 57,180 shares of company stock for an approximate total of $802,235. These sales were executed under a pre-arranged trading plan, while Rubinstein also acquired shares through option exercises. The company recently reported strong Q4 2025 earnings, surpassing analyst expectations, and received raised price targets from BTIG, TD Cowen, and Piper Sandler due to growth in its Minimal Residual Disease segment.
Adaptive Biotechnologies (ADPT) COO sells shares under Rule 10b5-1 plan
Adaptive Biotechnologies President and COO Julie Rubinstein exercised stock options and sold shares of common stock between March 24-26, 2026. She acquired 44,166 shares at an exercise price of $7.27 per share and subsequently sold 57,180 shares in open-market transactions at weighted average prices ranging from $13.45 to $14.49. All transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, and she now directly holds 468,892 shares.
[SCHEDULE 13G/A] Adaptive Biotechnologies Corp Amended Passive Investment Disclosure | ADPT SEC Filing
The Vanguard Group filed an Amended Schedule 13G/A for Adaptive Biotechnologies Corp, reporting 0 shares (0%) beneficially owned. This amendment stems from an internal realignment within Vanguard, disaggregating certain subsidiaries' holdings in reliance on SEC Release No. 34-39538. The filing clarifies reporting responsibilities rather than indicating an economic transaction, with subsequent filings by Vanguard subsidiaries expected to detail redistributed holdings.
Adaptive Biotechnologies (ADPT) president Rubinstein sells $769k in stock
Adaptive Biotechnologies (ADPT) President and COO, Julie Rubinstein, sold 57,180 shares of common stock for $769,642 between March 19-23, 2026, while also exercising options for 43,166 shares. This follows the company's strong fourth-quarter 2025 earnings, which surpassed analyst expectations, and several analysts raising price targets due to growth in its Minimal Residual Disease (MRD) business. Despite a 16% year-to-date loss, ADPT shares have seen a 63% return over the past year.
Adaptive Biotechnologies (ADPT) president Rubinstein sells $769k in stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies, sold 57,180 shares of company stock for over $769,000 between March 19-23, 2026, while also exercising options for 43,166 shares. This follows strong financial performance in Q4 2025, where the company exceeded analyst expectations for earnings and revenue. Analysts like BTIG, TD Cowen, and Piper Sandler have maintained or raised price targets for ADPT, citing growth in its Minimal Residual Disease (MRD) business.
Adaptive Biotechnologies (ADPT) COO sells 57K shares under 10b5-1 plan
Adaptive Biotechnologies' President and COO, Julie Rubinstein, exercised stock options for 44,166 shares and subsequently sold 57,180 shares in open-market transactions in March 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these sales, Rubinstein retains a direct holding of 481,906 shares in the company.
Adaptive Biotechnologies COO Rubinstein sells $762k in ADPT stock
Adaptive Biotechnologies' President and COO, Julie Rubinstein, sold 57,180 shares of ADPT stock for over $762,000 between March 16-18, 2026, while also exercising options for 44,166 shares. This follows strong Q4 2025 earnings which exceeded analyst expectations, leading to several analysts raising their price targets for the company. The stock is down 18% year-to-date but up 81% over the past year.
Adaptive Biotechnologies (ADPT) COO exercises options and sells 57,180 shares
Adaptive Biotechnologies' President and COO, Julie Rubinstein, exercised stock options to acquire 44,166 shares at $6.55 per share and subsequently sold 57,180 shares in open-market transactions at prices ranging from $13.18 to $13.41. These transactions occurred over three days, from March 16-18, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following these sales, Rubinstein directly owned 494,920 shares of the company's common stock.
18,672 RSUs registered for sale by filer (ADPT) via Morgan Stanley
Adaptive Biotechnologies Corp (ADPT) has filed a Rule 144 notice for the registration of 18,672 Restricted Stock Units (RSUs) for sale, handled by Morgan Stanley Smith Barney LLC. The filing also discloses prior open-market sales by Kyle Piskel involving 6,435 shares of common stock across two transactions in January and February 2026. The Securities Compliance Analyst notes this information without further specifying cash-flow treatment or whether the sales were brokered or private.
Chad Robins lists multiple ADPT share sales in Form 144 (ADPT)
Chad Robins filed a Form 144 to report proposed sales of Adaptive Biotechnologies Corp (ADPT) Common Stock. The filing details multiple transactions between January and March 2026, including a sale of 53,083 shares on March 3, 2026, and several sales on March 2 and February 27, 2026, along with other dates. Additionally, the form lists 140,567 Restricted Stock Units and 329,600 Performance Stock Units as of March 10, 2026.
[144] Adaptive Biotechnologies Corp SEC Filing
This article details an SEC Form 144 filing by Adaptive Biotechnologies Corp (ADPT), indicating a proposed sale of securities. The filing specifies the securities involved are Common Stock, with Morgan Stanley Smith Barney LLC as the broker, and notes the acquisition of these securities through Restricted Stock Units from the Issuer on March 10, 2026. The filing has a neutral impact and sentiment according to Rhea-AI.
ADPT (NASDAQ: ADPT) lists 140,666 RSUs and 329,600 PSUs in Rule 144 filing
Adaptive Biotechnologies Corp (ADPT) has filed a Rule 144 notice proposing the sale of 140,666 Restricted Stock Units (RSUs) and 329,600 Performance Stock Units (PSUs) through Morgan Stanley Smith Barney LLC, with an acquisition date of March 10, 2026. The filing also details open-market sales by Harlan Robins between January and March 2026, including multiple transactions of common stock. The aggregate market value of the securities to be sold is reported as $6,828,262.32, with 153,981,561 shares outstanding.
Insider sales at Adaptive Biotechnologies (NASDAQ: ADPT) include 122,523 RSUs
A recent Form 144 filing indicates that an insider at Adaptive Biotechnologies (NASDAQ: ADPT) is selling 122,523 Restricted Stock Units, with an effective date of March 10, 2026. The filing also details multiple open-market sales by Julie Rubinstein between March 3, 2026, and March 13, 2026, showing individual trade sizes and gross proceeds. The document provides specifics on the acquisition of these RSUs and a history of securities sold by Julie Rubinstein in the past three months.
Adaptive Biotechnologies’ chief scientific officer sells $6.19 million in stock
Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, sold over $6.19 million worth of common stock on March 11, 2026, to cover tax withholding obligations related to vested stock units. Despite the sale, Robins retains significant direct ownership in the company. This news follows strong Q4 2025 earnings for Adaptive Biotechnologies, which surpassed analyst expectations, leading to several analysts raising their price targets for the stock.
Insider Sell: Michelle Griffin Sells 15,394 Shares of Adaptive B
Michelle Griffin, a Director at Adaptive Biotechnologies Corp (ADPT), sold 15,394 shares of the company on March 11, 2026. This transaction follows a pattern where Griffin has sold a total of 63,438 shares over the past year with no purchases, and the company's stock is considered significantly overvalued based on its GF Value.
Adaptive Biotechnologies CCO Bobulsky sells $544k in ADPT stock By Investing.com
Susan Bobulsky, CCO of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 41,338 shares for $544,421 to cover tax obligations from vested RSUs. This transaction occurred amidst a stock decline of 11% over the past week, though shares are up 81% year-over-year. The company recently exceeded Q4 2025 earnings and revenue expectations, leading to several analysts raising their price targets and maintaining positive ratings.
Adaptive Biotechnologies’ chief scientific officer sells $6.19 million in stock
Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 470,266 shares totaling $6.19 million to cover tax withholding obligations from vested RSUs and performance share units. Despite a recent stock decline, ADPT has seen an 80.91% gain over the past year, though analysts suggest it is overvalued. The company recently surpassed Q4 2025 earnings expectations, leading to several analysts reiterating positive ratings and increasing price targets.
Adaptive Biotechnologies (ADPT) COO sells 179,703 shares under 10b5-1 plan
Adaptive Biotechnologies President and COO Julie Rubinstein reported the exercise of options for 44,166 shares and the sale of 179,703 shares of common stock in open-market transactions at various prices between $12.63 and $14.08. These transactions were conducted under a Rule 10b5-1 trading plan, with some sales covering tax withholding obligations. Following these trades, Rubinstein directly holds 507,934 shares and retains 62,827 fully vested stock options.
Insider Sell: Michelle Griffin Sells 15,394 Shares of Adaptive Biotechnologies Corp (ADPT)
Michelle Griffin, a Director at Adaptive Biotechnologies Corp (ADPT), sold 15,394 shares of the company on March 11, 2026. This transaction brings her total ownership to 15,625 shares, and the company has seen 37 insider sells with no buys over the past year. Shares were trading at $13.91, significantly above its GF Value of $9.69, indicating the stock is overvalued.
Adaptive Biotechnologies (ADPT) officer Lo sells 30,593 shares under 10b5-1 plan
Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold 30,593 shares of common stock at a weighted average price of $14.08 per share on March 11, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. Following the sale, Lo directly holds 291,374 shares and indirectly holds an additional 2,500 shares through a spouse.
Tax-driven share sale by Adaptive Biotechnologies (ADPT) chief commercial officer
Adaptive Biotechnologies' Chief Commercial Officer for Immune Medicine, Sharon Benzeno, sold 63,103 shares of common stock at $13.17 per share. This sale was a mandated "sell-to-cover" transaction to satisfy tax withholding obligations on vested restricted stock units, rather than a discretionary trade. Following the transaction, Benzeno directly holds 272,751 shares in the company, maintaining a significant equity position.
Adaptive Biotechnologies (ADPT) CEO sells shares to cover tax withholding
Adaptive Biotechnologies CEO Chad M. Robins sold 470,167 shares of common stock on March 11, 2026, at $13.17 per share. These sales were mandated "sell to cover" transactions to satisfy tax withholding obligations related to the vesting of RSUs and performance share units, not discretionary trades. After these transactions, Robins directly holds 2,301,113 shares of Adaptive Biotechnologies Common Stock.
Tax-driven share sale by Adaptive Biotechnologies (ADPT) Chief Scientific Officer
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 470,266 shares of common stock at $13.17 per share on March 11, 2026. This sale was a mandated "sell to cover" transaction to fulfill tax withholding obligations on vesting equity awards, not a discretionary trading decision. Following the transaction, Robins still directly owns 1,522,058 shares, indicating a continued significant stake in the company.
Adaptive Biotechnologies’ chief commercial officer sells $831k in stock
Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, sold 63,103 shares of common stock for over $831,000 to cover tax withholding obligations. This transaction occurred as the stock saw an 11% decline in the past week, despite an 81% gain over the last year. The company recently exceeded analyst expectations in Q4 2025 earnings, with analysts from BTIG, TD Cowen, and Piper Sandler giving positive outlooks and raising price targets.
Adaptive Biotechnologies Executives Sell Shares to Cover Tax Obligations
Several executives at Adaptive Biotechnologies Corp. (ADPT) recently sold company shares to cover tax obligations arising from vested Restricted Stock Units (RSUs) and performance share units. CEO Chad M Robins, President Julie Rubinstein, CSO Harlan S. Robins, and CCOs Sharon Benzeno and Susan Bobulsky were among those who sold shares, with the transactions totaling millions of dollars. Despite these sales, the executives retain significant direct ownership in the company.
Adaptive Biotechnologies Executives Sell Shares for Tax Obligations
Several Adaptive Biotechnologies executives, including CEO Chad M Robins, President and COO Julie Rubinstein, and Chief Scientific Officer Harlan S. Robins, sold significant amounts of company stock. These sales were primarily conducted to cover tax withholding obligations arising from the vesting of Restricted Stock Units and performance share units. The transactions involved millions of dollars and have adjusted the direct ownership stakes of the executives involved.
Michelle Griffin sells 48,044 ADPT shares (ADPT) for $735K
Michelle Griffin, an insider at Adaptive Biotechnologies Corp (ADPT), reported the sale of 48,044 common stock shares on March 3, 2026, for a total of $735,299.01. The Form 144 filing also noted 15,394 restricted shares associated with Morgan Stanley Smith Barney LLC, dated March 4, 2026. This transaction is characterized as a routine insider sale.
Francis Lo reports multiple 10b5-1 share sales for ADPT (NASDAQ: ADPT)
Francis Lo, an insider at Adaptive Biotechnologies Corp (NASDAQ: ADPT), has reported multiple share disposals under a Rule 144 filing and 10b5-1 plan. The transactions include the sale of 38,074 shares for $574,536.66 on March 5, 2026, and 79,590 shares for $1,411,393.35 on January 12, 2026. The filing also notes 30,593 Restricted Stock Units acquired on March 4, 2025.
Adaptive Biotechnologies Executive Sells Over $1.2 Million in Company Stock
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold 81,342 shares of company stock in early March 2026 for a total of $1,211,736. These sales were conducted under a Rule 10b5-1 trading plan. Following these transactions, Rubinstein directly owns 643,471 shares of Adaptive Biotechnologies Corp.
Lo Francis, chief people officer at Adaptive Biotechnologies, sells $574k in ADPT
Lo Francis, Chief People Officer at Adaptive Biotechnologies (NASDAQ:ADPT), sold 38,074 shares of common stock for $574,536 on March 5, 2026, to cover tax withholding obligations. This transaction occurred amidst a 7% stock decline over the past week, although shares have surged 124% over the past year. The company recently reported strong Q4 2025 earnings, exceeding analyst expectations, leading to raised price targets from TD Cowen and BTIG.
[Form 4] Adaptive Biotechnologies Corp Insider Trading Activity
Adaptive Biotechnologies Corp President and COO Julie Rubinstein engaged in an exercise-and-sell transaction in March 2026, as reported in a Form 4 filing. She exercised stock options for 68,328 shares and subsequently sold 81,342 shares through a pre-arranged Rule 10b5-1 trading plan. Following these trades, Rubinstein directly holds 643,471 shares of Common Stock.
Do Insider Sales Align With Adaptive Biotechnologies' (ADPT) MRD-Driven Momentum and Long-Term Strategy?
Adaptive Biotechnologies reported strong Q4 2025 results driven by its Minimal Residual Disease (MRD) business, while also filing a significant shelf registration for shares tied to an employee stock ownership plan. Concurrently, the CEO and CSO conducted sizable preplanned stock sales. The article raises questions about potential future dilution and the company's ability to fund unprofitability, balancing the positive MRD momentum against insider selling and equity issuance.
Adaptive Biotechnologies (ADPT) CFO receives 61,875-share stock grant
Adaptive Biotechnologies Corp (ADPT) Chief Financial Officer, Kyle Piskel, was awarded 61,875 shares of common stock as a grant on March 4, 2026. These shares were granted at $0.00 per share, indicating they were compensation rather than a market purchase. Following this transaction, Piskel's direct ownership in the company increased to 278,512 shares.
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold approximately $1.49 million in company shares between March 3 and March 5, 2026, while also acquiring shares through stock option exercises worth $721,993. These transactions were executed under a Rule 10b5-1 trading plan. The company recently reported strong fourth-quarter 2025 earnings, surpassing analyst expectations for EPS and revenue, leading to raised price targets from TD Cowen and BTIG.
Adaptive Biotechnologies’ Rubinstein sells $1.49m in shares By Investing.com
Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, sold 92,823 shares worth approximately $1.49 million between March 3 and March 5, 2026, while also exercising options to acquire 73,610 shares. These transactions were under a Rule 10b5-1 trading plan. The company recently reported strong Q4 2025 earnings, exceeding analyst expectations, leading to increased price targets from TD Cowen and BTIG.
Adaptive Biotechnologies Corp. Achieves 102.46% Yearly Gain, Establishing It as a Multibagger Stock
Adaptive Biotechnologies Corp. has achieved a 102.46% yearly gain, establishing it as a multibagger stock. The company has shown consistent growth with a 13.44% increase in net sales and positive results for four consecutive quarters, reaching USD 165.65 million in net sales. High institutional holdings and a market capitalization of approximately USD 2.47 billion underscore its strong market position and potential in the biotechnology sector.
Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock
Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies (NASDAQ:ADPT), sold 24,233 shares of company stock on March 2nd and 3rd, 2026, totaling approximately $392,329. These sales were part of a Rule 10b5-1 trading plan. The company recently surpassed Q4 2025 earnings and revenue expectations, leading to increased price targets from analysts, despite an InvestingPro analysis suggesting the stock may be overvalued.
Adaptive Biotechnologies CSO Robins sells $392,329 in ADPT stock By Investing.com
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 24,233 shares of ADPT stock for approximately $392,329 on March 2nd and 3rd, 2026, under a Rule 10b5-1 trading plan. These sales occurred as ADPT shares traded at $16.44, with the company boasting a $2.54 billion market capitalization and a 105% return over the past year. Despite a recent earnings beat and analyst price target increases, InvestingPro analysis suggests the stock may be overvalued.
Insider Sell: Harlan Robins Sells 24,233 Shares of Adaptive Biotechnologies Corp (ADPT)
Harlan Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), sold 24,233 shares of the company on March 3, 2026. This transaction increased his total sales over the past year to 290,999 shares, with no purchases. Shares of ADPT were trading at $16.19 at the time of the sale, significantly overvalued compared to its GF Value estimate of $8.83.
